Q-omics provides the consensus-scored HIGD1C profile across patient tissues and cancer cell-line models. HIGD1C expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, HIGD1C is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, HIGD1C RNA expression shows 10,761 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight MESO, KIRC, and ESCA as cancer lineages where HIGD1C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HIGD1C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HIGD1C survival associations across molecular data types. HIGD1C RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HIGD1C RNA expression–survival associations across cancer types. High HIGD1C expression shows unfavorable associations in COAD and LGG, but favorable associations in MESO, BLCA, CESC and ACC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for HIGD1C RNA expression.
This table summarizes HIGD1C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HIGD1C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HIGD1C shows lower tumor expression in THCA, BRCA, COAD, BLCA and LUSC and higher tumor expression in KIRC. The KIRC box plot shows higher HIGD1C RNA expression in tumor versus normal tissue (log2 FC = +0.140, t-test p = .001).
This table shows molecular features associated with HIGD1C in patient tissues and cancer cell lines. In patient samples, HIGD1C shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, HIGD1C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
